Antibiotic-Loaded Nano-Sized Delivery Systems: An Insight into Gentamicin and Vancomycin
Source abstract
Abstract
The fight against infectious disease has remained an ever-evolving challenge in the landscape of healthcare. The ability of pathogens to develop resistance against conventional drug treatments has decreased the effectiveness of therapeutic interventions, and antibiotic resistance is recognized as one of the main challenges of our time. The goal of this systematic review paper is to provide insight into the research papers published on innovative nanosized drug delivery systems (DDSs) based on gentamycin and vancomycin and to discuss the opportunity of their repurposing through nano DDS formulations. These two antibiotics are selected because (i) gentamicin is the first-line drug used to treat suspected or confirmed infections caused by Gram-negative bacterial infections and (ii) vancomycin is used to treat serious Gram-positive bacterial infections. Moreover, both antibiotics have severe adverse effects, and one of the purposes of their formulation as nanosized DDSs is to overcome them. The review paper includes an introduction focusing on the challenges of infectious diseases and traditional therapeutic treatments, a brief description of the chemical and pharmacological properties of gentamicin and vancomycin, case studies from the literature on innovative nanosized DDSs as carriers of the two antibiotic drugs, and a discussion of the results found in the literature.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy
Department of Drug Sciences, IUSS Scuola Universitaria Superiore Pavia, 27100 Pavia, Italy
Funding
EU funding within the NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
References (100+)
Show source-provided references
1. (2024). WHO Bacterial Priority Pathogens List 2024, World Health Organization. Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance.
2. Drug delivery for fighting infectious diseases: A global perspective10.1007/s13346-021-01009-1 ↗
3. Graef, F., Gordon, S., and Lehr, C.-M. (2016). Anti-infectives in drug delivery—Overcoming the gram-negative bacterial cell envelope. How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives, Springer.10.1007/82_2016_491 ↗
4. Advances in drug delivery systems, challenges and future directions10.1016/j.heliyon.2023.e17488 ↗
5. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease
6. Strugnell, R.A., Newton, H.J., and Kupz, A. (2024). Survival strategies of intracellular bacterial pathogens. Molecular Medical Microbiology, Elsevier.10.1016/B978-0-12-818619-0.00105-2 ↗
7. Strategies for the eradication of intracellular bacterial pathogens10.1039/D3BM01498C ↗
8. Nanoparticle-based methodologies for targeted drug delivery—An insight10.1007/s11051-021-05190-9 ↗
9. Nano based drug delivery systems: Recent developments and future prospects10.1186/s12951-018-0392-8 ↗
10. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection
11. (2024, May 01). European Pharmacopoeia 11th Edition. Available online: https://www.edqm.eu/en/european-pharmacopoeia-ph.-eur.-11th-edition.
12. Enhanced Bactericidal Effects and Drug Delivery with Gentamicin-Conjugated Nanoparticles10.1007/s10876-023-02501-z ↗
13. Assessment of the efficacy, safety and quality of gentamicin use in Aberdeen Royal Infirmary10.1093/jac/44.6.843 ↗
14. Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: An updated review10.1007/s40262-022-01143-0 ↗
15. Pharmacokinetics of gentamicin in children and adults10.1093/infdis/132.6.637 ↗
16. Mechanisms of gentamicin resistance in Staphylococcus aureus10.1128/AAC.11.1.47 ↗
17. Stability of vancomycin hydrochloride solutions in high concentration and extended time of infusion10.1186/2197-425X-3-S1-A717 ↗
18. Tsutsuura, M., Moriyama, H., Kojima, N., Mizukami, Y., Tashiro, S., Osa, S., Enoki, Y., Taguchi, K., Oda, K., and Fujii, S. (2021). The monitoring of vancomycin: A systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect. Dis., 21.10.1186/s12879-021-05858-6 ↗
19. Haseeb, A., Alqurashi, M.K., Althaqafi, A.S., Alsharif, J.M., Faidah, H.S., Bushyah, M., Alotaibi, A.F., Elrggal, M.E., Mahrous, A.J., and Abuhussain, S.S.A. (2022). A systematic review on clinical safety and efficacy of vancomycin loading dose in critically ill patients. Antibiotics, 11.10.3390/antibiotics11030409 ↗
20. Vancomycin: A History10.1086/491709 ↗
21. Vancomycin resistance: Occurrence, mechanisms and strategies to combat it10.1517/14728222.7.3.311 ↗
22. Prevalence of Vancomycin-resistant enterococci (VRE) in Egypt (2010–2022): A systematic review and meta-analysis10.1186/s42506-023-00133-9 ↗
23. Sparo, M., Delpech, G., and García Allende, N. (2018). Impact on public health of the spread of high-level resistance to gentamicin and vancomycin in enterococci. Front. Microbiol., 9.10.3389/fmicb.2018.03073 ↗
24. Controlled release and targeted drug delivery with poly (lactic-co-glycolic acid) nanoparticles: Reviewing two decades of research10.1007/s40005-022-00584-w ↗
25. Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: Research progress, challenges, and prospects10.1007/s11274-021-03070-x ↗
26. Combination of vancomycin and guanidinium-functionalized helical polymers for synergistic antibacterial activity and biofilm ablation10.1039/D2SC03419K ↗
27. Mishra, M., Patole, S., and Mohapatra, H. (2021). Nanoparticles: Powerful tool to mitigate antibiotic resistance. Sustainable Agriculture Reviews 49: Mitigation of Antimicrobial Resistance Vol 2. Natural and Synthetic Approaches, Springer.10.1007/978-3-030-58259-3_6 ↗
28. Physicochemical characterization and antimicrobial evaluation of gentamicin-loaded CaCO3 nanoparticles prepared via microemulsion method10.1016/j.jddst.2016.05.004 ↗
29. Mosselhy, D.A., Ge, Y., Gasik, M., Nordström, K., Natri, O., and Hannula, S.-P. (2016). Silica-gentamicin nanohybrids: Synthesis and antimicrobial action. Materials, 9.10.3390/ma9030170 ↗
30. Gentamicin coated iron oxide nanoparticles as novel antibacterial agents10.1088/2053-1591/aa8652 ↗
31. Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities10.2147/IJN.S141709 ↗
32. Clearance of intracellular Klebsiella pneumoniae infection using gentamicin-loaded nanoparticles10.1016/j.jconrel.2018.04.040 ↗
33. Pan, X., Chen, S., Li, D., Rao, W., Zheng, Y., Yang, Z., Li, L., Guan, X., and Chen, Z. (2018). The synergistic antibacterial mechanism of gentamicin-loaded CaCO3 nanoparticles. Front. Chem., 5.10.3389/fchem.2017.00130 ↗
34. Gentamicin-loaded chitosan nanoparticles improve its therapeutic effects on brucella-infected J774A. 1 murine cells10.31661/gmj.v8i0.1296 ↗
35. Gentamicin-loaded silk/nanosilver composite scaffolds for MRSA-induced chronic osteomyelitis10.1098/rsos.182102 ↗
36. In vitro and in vivo evaluation of gentamicin sulphate-loaded PLGA nanoparticle-based film for the treatment of surgical site infection10.1007/s13346-020-00730-7 ↗
37. Antimicrobial proanthocyanidin-chitosan composite nanoparticles loaded with gentamicin10.1016/j.ijbiomac.2020.07.213 ↗
38. Synthesis and characterizations of gentamicin-loaded poly-lactic-co-glycolic (PLGA) nanoparticles10.1007/s11051-021-05293-3 ↗
39. Characterization and Evaluation The Biological Activity of Prepared Nano-Gentamicin Nanoparticles10.1088/1755-1315/910/1/012078 ↗
40. Kazeminava, F., Javanbakht, S., Nouri, M., Gholizadeh, P., Nezhad-Mokhtari, P., Ganbarov, K., Tanomand, A., and Kafil, H.S. (2022). Gentamicin-loaded chitosan/folic acid-based carbon quantum dots nanocomposite hydrogel films as potential antimicrobial wound dressing. J. Biol. Eng., 16.10.1186/s13036-022-00318-4 ↗
41. Abdel-Hakeem, M.A., Abdel Maksoud, A.I., Aladhadh, M.A., Almuryif, K.A., Elsanhoty, R.M., and Elebeedy, D. (2022). Gentamicin–Ascorbic Acid Encapsulated in Chitosan Nanoparticles Improved In Vitro Antimicrobial Activity and Minimized Cytotoxicity. Antibiotics, 11.10.3390/antibiotics11111530 ↗
42. Incorporation of gentamicin-encapsulated poly (lactic-co-glycolic acid) nanoparticles into polyurethane/poly (ethylene oxide) nanofiber scaffolds for biomedical applications10.1021/acsanm.3c03549 ↗
43. Dorati, R., DeTrizio, A., Spalla, M., Migliavacca, R., Pagani, L., Pisani, S., Chiesa, E., Conti, B., Modena, T., and Genta, I. (2018). Gentamicin sulfate PEG-PLGA/PLGA-H nanoparticles: Screening design and antimicrobial effect evaluation toward clinic bacterial isolates. Nanomaterials, 8.10.3390/nano8010037 ↗
44. Vancomycin functionalized nanoparticles for bactericidal biomaterial surfaces10.1021/acs.biomac.5b01727 ↗
45. Vancomycin-functionalized gold and silver nanoparticles as an antibacterial nanoplatform against methicillin-resistant Staphylococcus aureus10.1166/jnn.2016.12393 ↗
46. Spanish Broom (Spartium junceum L.) fibers impregnated with vancomycin-loaded chitosan nanoparticles as new antibacterial wound dressing: Preparation, characterization and antibacterial activity10.1016/j.ejps.2016.11.028 ↗
47. Zhang, Y., Liang, R.-J., Xu, J.-J., Shen, L.-F., Gao, J.-Q., Wang, X.-P., Wang, N.-N., Shou, D., and Hu, Y. (2017). Efficient induction of antimicrobial activity with vancomycin nanoparticle-loaded poly (trimethylene carbonate) localized drug delivery system. Int. J. Nanomed., 1201–1214.10.2147/IJN.S127715 ↗
48. Bhise, K., Sau, S., Kebriaei, R., Rice, S.A., Stamper, K.C., Alsaab, H.O., Rybak, M.J., and Iyer, A.K. (2018). Combination of vancomycin and cefazolin lipid nanoparticles for overcoming antibiotic resistance of MRSA. Materials, 11.10.3390/ma11071245 ↗
49. Development and characterization of PLGA nanoparticles containing antibiotics10.1007/s11051-018-4387-z ↗
50. Synergetic effect of vancomycin loaded silver nanoparticles for enhanced antibacterial activity10.1016/j.colsurfb.2018.12.043 ↗
51. Chen, Y.-H., Li, T.-J., and Tsai, P.-J. (2019). Vancomycin-loaded nanoparticles enhance sporicidal and antibacterial efficacy for Clostridium difficile infection. Front. Microbiol., 10.10.3389/fmicb.2019.01141 ↗
52. Vancomycin-loaded nanoparticles against vancomycin intermediate and methicillin resistant Staphylococcus aureus strains10.1088/1361-6528/ab97d7 ↗
53. Formulation of biocompatible vancomycin conjugated gold nanoparticles for enhanced antibacterial efficacy
54. Nader, D., Yousef, F., Kavanagh, N., Ryan, B.K., and Kerrigan, S.W. (2021). Targeting internalized Staphylococcus aureus using vancomycin-loaded nanoparticles to treat recurrent bloodstream infections. Antibiotics, 10.10.3390/antibiotics10050581 ↗
55. Hagbani, T.A., Yadav, H., Moin, A., Lila, A.S.A., Mehmood, K., Alshammari, F., Khan, S., Khafagy, E.-S., Hussain, T., and Rizvi, S.M.D. (2022). Enhancement of vancomycin potential against pathogenic bacterial strains via gold nano-formulations: A nano-antibiotic approach. Materials, 15.10.3390/ma15031108 ↗
56. Synthesis and characterization of vancomycin-loaded chitosan nanoparticles for drug delivery10.1007/s00289-022-04237-8 ↗
57. Nouruzi, E., Hosseini, S.M., Asghari, B., Mahjoub, R., Zare, E.N., Shahbazi, M.-A., Kalhori, F., and Arabestani, M.R. (2023). Effect of poly (lactic-co-glycolic acid) polymer nanoparticles loaded with vancomycin against Staphylococcus aureus biofilm. BMC Biotechnol., 23.10.1186/s12896-023-00811-8 ↗
58. Zong, T.-X., Silveira, A.P., Morais, J.A.V., Sampaio, M.C., Muehlmann, L.A., Zhang, J., Jiang, C.-S., and Liu, S.-K. (2022). Recent advances in antimicrobial nano-drug delivery systems. Nanomaterials, 12.10.3390/nano12111855 ↗
59. Pisani, S., Dorati, R., Chiesa, E., Genta, I., Modena, T., Bruni, G., Grisoli, P., and Conti, B. (2019). Release profile of gentamicin sulfate from polylactide-co-polycaprolactone electrospun nanofiber matrices. Pharmaceutics, 11.10.3390/pharmaceutics11040161 ↗
60. Simpson, E., Sarwar, H., Jack, I., and Lowry, D. (2024). Evaluation of the Potential of Chitosan Nanoparticles as a Delivery Vehicle for Gentamicin for the treatment of Osteomyelitis. Antibiotics, 13.10.3390/antibiotics13030208 ↗
61. Ural, M.S., Menéndez-Miranda, M., Salzano, G., Mathurin, J., Aybeke, E.N., Deniset-Besseau, A., Dazzi, A., Porcino, M., Martineau-Corcos, C., and Gref, R. (2021). Compartmentalized Polymeric Nanoparticles Deliver Vancomycin in a pH-Responsive Manner. Pharmaceutics, 13.10.3390/pharmaceutics13121992 ↗
62. Preparation and evaluation of vancomycin-loaded N-trimethyl chitosan nanoparticles10.3390/polym7091488 ↗
63. Smart multifunctional polymer systems as alternatives or supplements of antibiotics to overcome bacterial resistance10.1021/acs.biomac.1c01614 ↗
64. Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid cleavable lipid10.1016/j.nano.2017.04.010 ↗
65. Magnetic stimulus responsive vancomycin drug delivery system based on chitosan microbeads embedded with magnetic nanoparticles10.1002/jbm.b.34015 ↗
66. Enhanced efficacy and broadening of antibacterial action of drugs via the use of capped mesoporous nanoparticles10.1002/chem.201302170 ↗
67. One-pot synthesis of vancomycin-encapsulated ZIF-8 nanoparticles as multivalent and photocatalytic antibacterial agents for selective-killing of pathogenic gram-positive bacteria10.1007/s10853-021-05828-y ↗
68. Vancomycin conjugated iron oxide nanoparticles for magnetic targeting and efficient capture of Gram-positive and Gram-negative bacteria10.1039/D1RA04390K ↗
69. One pot synthesis of gentamicin conjugated gold nanoparticles as an efficient antibacterial agent10.1007/s10876-020-01864-x ↗
70. Liposome-mediated gentamicin delivery: Development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients10.1093/jac/dkh518 ↗
71. Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid10.3109/13880209.2014.895018 ↗
72. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria10.1016/j.ijantimicag.2010.01.015 ↗
73. Preparation and in vivo evaluation of nanoliposomes containing vancomycin after intravitreal injection in albino rabbits
74. Joshi, M.D., Iacoban, P., and Scheetz, M.H. (2023). Pharmacokinetic and biomarker quantification studies on vancomycin-loaded PEGylated liposomes and its potential to reduce vancomycin-induced kidney injury: A rat study. Pharmaceutics, 15.10.3390/pharmaceutics15061582 ↗
75. Liposomal delivery of antibiotic loaded nucleic acid nanogels with enhanced drug loading and synergistic anti-inflammatory activity against S. aureus intracellular infections10.1016/j.jconrel.2020.06.002 ↗
76. Wang, J., Li, B., Qiu, L., Qiao, X., and Yang, H. (2022). Dendrimer-based drug delivery systems: History, challenges, and latest developments. J. Biol. Eng., 16.10.1186/s13036-022-00298-5 ↗
77. Discovery of dendrimers and dendritic polymers: A brief historical perspective10.1002/pola.10301 ↗
78. Conjugation of Gentamicin to Polyamidoamine Dendrimers Improved Anti-bacterial Properties against Pseudomonas aeruginosa10.34172/apb.2021.076 ↗
79. Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated S. aureus10.1021/acsinfecdis.3c00168 ↗
80. The pH-controlled dual-drug release from mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites10.1016/j.ejpb.2007.11.018 ↗
81. Antibacterial micelles with vancomycin-mediated targeting and pH/lipase-triggered release of antibiotics10.1021/acsami.8b16092 ↗
82. Functionalized carbon nanotubes: Synthesis, properties and applications in water purification, drug delivery, and material and biomedical sciences10.1039/D1NA00293G ↗
83. Rosen, Y., and Gurman, P. (2014). Carbon nanotubes for drug delivery applications. Nanotechnology and Drug Delivery, CRC Press.10.1201/b17271-8 ↗
84. Carbon nanotubes: Smart drug/gene delivery carriers10.2147/IJN.S299448 ↗
85. Fabrication of antibacterial electrospun nanofibers with vancomycin-carbon nanotube via ultrasonication assistance10.1016/j.matdes.2017.02.008 ↗
86. Al Thaher, Y., Khalil, R., Abdelghany, S., and Salem, M.S. (2022). Antimicrobial PMMA bone cement containing long releasing multi-walled carbon nanotubes. Nanomaterials, 12.10.3390/nano12081381 ↗
87. Bacterial anti-microbial peptides and nano-sized drug delivery systems: The state of the art toward improved bacteriocins10.1016/j.jconrel.2020.02.001 ↗
88. Sangiorgio, G., Nicitra, E., Bivona, D., Bonomo, C., Bonacci, P., Santagati, M., Musso, N., Bongiorno, D., and Stefani, S. (2024). Interactions of Gram-Positive Bacterial Membrane Vesicles and Hosts: Updates and Future Directions. Int. J. Mol. Sci., 25.10.3390/ijms25052904 ↗
89. Tackling the outer membrane: Facilitating compound entry into Gram-negative bacterial pathogens10.1038/s44259-023-00016-1 ↗
90. The Gram-positive bacterial cell wall10.1128/microbiolspec.GPP3-0044-2018 ↗
91. Targeting bacterial membrane function: An underexploited mechanism for treating persistent infections10.1038/nrmicro2474 ↗
92. Liposomes as a carrier for gentamicin delivery: Development and evaluation of the physicochemical properties10.1016/j.ijpharm.2008.03.035 ↗
93. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes10.1128/AAC.42.10.2511 ↗
94. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A time–kill study10.1016/j.ijantimicag.2005.10.021 ↗
95. Investigating the Antimicrobial Efficacy of Liposomal Vancomycin in Gram-positive and Gram-negative bacteria-A Preliminary Mechanistic Study: Antimicrobial Effects of Liposomal Vancomycin
96. Development and stability studies of novel liposomal vancomycin formulations
97. Design and development of vancomycin liposomes10.5530/ijper.49.3.6 ↗
98. Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model10.1093/jac/dks212 ↗
99. Liposomal drug delivery systems: From concept to clinical applications10.1016/j.addr.2012.09.037 ↗
100. Liposome: Classification, preparation, and applications10.1186/1556-276X-8-102 ↗